Ayvaco

Ayvaco is a biotechnology company specializing in the development of synthetic DNA vaccines and immunotherapies for infectious diseases and cancer. Spun out from The Wistar Institute, the company utilizes a proprietary platform to create DNA-based candidates that are thermally stable and capable of inducing potent immune responses. Ayvaco's lead program, AV-001, is a vaccine candidate targeting COVID-19, designed to provide broad protection against variants. The company's leadership includes world-renowned experts in DNA vaccinology and immunology. Ayvaco aims to streamline vaccine production and distribution to improve global access to life-saving preventatives.